# Lixte Biotechnology Holdings, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Lixte Biotechnology Holdings, Inc). ## Overview NOMAD POWER SOLUTIONS, INC. is a U.S.-based clinical-stage biopharmaceutical company focused on developing cancer therapies built around protein phosphatase 2A (PP2A) inhibition. Its work centers on the lead compound LB-100 and related oncology drug-development activities, including clinical research, patent protection, and licensing arrangements. ## Products & services • LB-100 oncology drug candidate • PP2A inhibitor-based cancer therapies • Clinical trial development programs • Patent and licensing rights for drug candidates • Collaborative research and sublicense arrangements - **Lead drug candidate development** (70%) — Development of LB-100 and related PP2A inhibitor oncology assets. - **Clinical research programs** (20%) — Preclinical and clinical trial work supporting cancer drug development. - **Licensing and royalty rights** (10%) — License agreements, sublicensing rights, and royalty-bearing arrangements. - LB-100 oncology drug candidate - PP2A inhibitor-based cancer therapies - Clinical trial development programs - Patent and licensing rights for drug candidates - Collaborative research and sublicense arrangements ## Customers The company’s direct counterparties are primarily pharmaceutical companies, clinical trial sites, research collaborators, and licensors rather than end-patient buyers. Its therapies are developed for oncology use, so eventual commercial customers would be healthcare providers, hospitals, and cancer treatment centers if products reach approval and market launch. - **Pharmaceutical collaborators** (primary) — Companies that may partner on development, trials, or commercialization of LB-100 and related assets. - **Clinical trial sites** (primary) — Hospitals and cancer centers that enroll patients and generate clinical data for regulatory filings. - **Licensing counterparties** (secondary) — Organizations involved in license, sublicense, and royalty arrangements tied to the company’s IP. - **Future oncology providers** (emerging) — Hospitals, cancer centers, and physicians that would use approved therapies in practice. - Pharmaceutical partners supporting trials and commercialization - Clinical trial sites running oncology studies - Cancer centers participating in research programs - Licensors and sublicensees in royalty-bearing agreements - Future hospitals and oncology providers, if approved ## Geography The company is headquartered in Pasadena, California and operates as a U.S.-based development-stage business. Its disclosed licensing obligations are country-by-country, indicating that future commercialization and royalty exposure may extend across multiple approved markets rather than a single geography. - Headquartered in Pasadena, California - Core operations are managed from the United States - Clinical and regulatory work may extend into licensed territories - Royalty obligations are tracked on a country-by-country basis - Future commercialization depends on approvals in each market ## Strategy The company’s strategy is to advance LB-100 through clinical development, generate supporting data, and pursue regulatory and commercialization pathways for oncology use. It also seeks to protect and extend value through patents, licensing, and potential collaborations with pharmaceutical companies and clinical sites. - **Advance LB-100 clinical development** (short-term) — Clinical progress is the main path to value creation for a single-asset oncology company. - **Secure additional capital** (short-term) — Development-stage biopharma requires external funding to continue trials and development. - **Build licensing and IP value** (medium-term) — Patent and license rights can support future commercialization and partnering economics. - Advance LB-100 through clinical development - Generate data to support regulatory filings - Pursue oncology partnerships and collaborations - Protect value through patents and licensing - Preserve optionality for commercialization or alliances ## Risks The company faces the typical risks of a clinical-stage biopharmaceutical developer: trial failure, regulatory delay, and dependence on external funding. Because it has not yet generated revenue, its ability to continue operations depends on capital access, while licensing obligations and royalty commitments can affect future economics if commercialization occurs. - **Financing risk** [critical] — The company must raise additional capital to fund clinical development and operations. - **Clinical development risk** [high] — LB-100 may not show sufficient efficacy or safety in trials to support approval. - **Regulatory risk** [high] — Marketing approval depends on successful filings and regulator acceptance in each territory. - **Intellectual property risk** [medium] — Patent scope, validity, and license terms affect exclusivity and commercialization value. - **Royalty obligation risk** [medium] — Future sales or sublicensing revenue may be subject to NIH royalties and minimum payments. - No revenue-generating operations yet - Depends on equity capital to fund development - Clinical trial outcomes may not support approval - Regulatory approvals may be delayed or denied - Royalty and license obligations reduce future economics ## Accounting Key accounting judgments center on clinical trial accruals, contingent liabilities, and the valuation of equity instruments issued for services. Because the company has no revenue, reported results are driven mainly by development expenses, stock-based compensation, and estimates tied to license commitments and other obligations. - **Clinical trial accruals** — Research and development expense - **Equity compensation valuation** — General and administrative expense - **License royalty commitments** — Other liabilities and cash outflows - **Stock-based compensation** — Operating expenses and share count - Clinical trial accrual estimates affect research and development expense - Equity instruments issued for services require fair value estimates - License commitments create long-term accrued obligations - Stock-based compensation can materially affect operating expense - No revenue means expense timing drives reported results --- *Last updated: 2026-09-24T12:13:34.350253+00:00*